Paul Klekotka
Overview
Explore the profile of Paul Klekotka including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
3356
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vesely M, Lizzul P, Klekotka P, Joller N, Raff A
J Invest Dermatol
. 2025 Feb;
PMID: 39927905
No abstract available.
2.
Ramirez S, Lopez P, Faraji F, Parikh U, Heaps A, Ritz J, et al.
JCI Insight
. 2024 Dec;
9(24).
PMID: 39704169
T cells are involved in protective immunity against numerous viral infections. Data regarding functional roles of human T cells in SARS-CoV-2 (SARS2) viral clearance in primary COVID-19 are limited. To...
3.
Klekotka P, Lavoie L, Mitchell B, Iheanacho I, Burge R, Cohee A, et al.
Front Immunol
. 2024 Nov;
15:1425478.
PMID: 39483464
Introduction: Several current therapies for autoimmune diseases do not provide sustained remission. Therapies that focus on the restoration of homeostasis within the immune system (i.e., immune resolution) could overcome the...
4.
Paul M, Choudhary M, Heaps A, Deo R, Moisi D, Gordon K, et al.
Pathog Immun
. 2024 Sep;
9(2):79-93.
PMID: 39247686
Background: Anti-SARS-CoV-2 monoclonal antibodies (mAbs) have played a key role as an anti-viral against SARS-CoV-2, but there is a potential for resistance to develop. The interplay between host antibody responses...
5.
Patel D, Macpherson L, Bohm M, Upadhyaya H, Deveau C, Nirula A, et al.
Infect Dis Ther
. 2024 Sep;
13(10):2123-2134.
PMID: 39230829
Introduction: The monoclonal antibody therapies bamlanivimab (BAM) + etesevimab (ETE) received emergency use authorization (EUA) from the US Food and Drug Administration (February 9, 2021) for treatment of mild-to-moderate COVID-19....
6.
Parikh U, Heaps A, Moisi D, Gordon K, Mellors J, Choudhary M, et al.
Pathog Immun
. 2024 Aug;
9(2):58-78.
PMID: 39165724
Background: Assessing the breadth and duration of antigen-specific binding antibodies provides valuable information for evaluating interventions to treat or prevent SARS-CoV-2 infection. Multiplex immunoassays are a convenient method for rapid...
7.
Bloom N, Ramirez S, Cohn H, Parikh U, Heaps A, Sieg S, et al.
J Infect Dis
. 2024 Jul;
230(5):1187-1196.
PMID: 39036987
Therapeutic monoclonal antibodies (mAbs) have been studied in humans, but the impact on immune memory of mAb treatment during an ongoing infection remains unclear. We evaluated the effect of infusion...
8.
Coelho C, Bloom N, Ramirez S, Parikh U, Heaps A, Sieg S, et al.
bioRxiv
. 2023 Dec;
PMID: 38045374
Therapeutic anti-SARS-CoV-2 monoclonal antibodies (mAbs) have been extensively studied in humans, but the impact on immune memory of mAb treatment during an ongoing immune response has remained unclear. Here, we...
9.
Ramirez S, Lopez P, Faraji F, Parikh U, Heaps A, Ritz J, et al.
bioRxiv
. 2023 Nov;
PMID: 37961119
T cells are involved in protective immunity against numerous viral infections. Data regarding functional roles of human T cells in SARS-CoV-2 (SARS2) viral clearance in primary COVID-19 are limited. To...
10.
Evering T, Moser C, Jilg N, Yeh E, Sanusi B, Wohl D, et al.
J Infect Dis
. 2023 Aug;
228(Suppl 2):S126-S135.
PMID: 37650236
Background: Prospective evaluations of long COVID in outpatients with coronavirus disease 2019 (COVID-19) are lacking. We aimed to determine the frequency and predictors of long COVID after treatment with the...